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Abstract
Background: We aimed to investigate the effects of brachytherapy, drug-eluting stent (DES)
and bare metal stent (BMS) applications in the treatment of coronary artery disease, on five-
-year clinical outcomes and mortality.
Methods: Two hundred and seventeen patients who were treated in our clinics between
January 2000 and December 2003 with brachytherapy, DES, or BMS for both de novo and in-
-stent restenosis lesions were included in this cohort study. Of these 217 patients, 69 received
brachytherapy, 80 were given BMS and 68 were given DES. The clinical outcomes of the
patients during hospitalization and over a long-term follow-up were evaluated. Cardiovascu-
lar events, revascularizations and mortality rates were compared among the three groups over
a five-year follow-up.
Results: The mean age was 60.1 ± 9.5 years in the brachytherapy group, 55.7 ± 9.2 years in
the BMS group, and 58.9 ± 9.8 years in the DES group (p = 0.44). All-cause mortality rates
were 20 (29%) brachytherapy patients, 22 (27.5%) BMS patients, and four (5.9%) DES
patients (p = 0.01). Cardiovascular event was the cause of death for 14 (20.3%) brachytherapy
patients, 16 (20%) BMS patients and four (5.9%) DES patients (p = 0.001). All-cause
mortality rates were 20 (29%) brachytherapy patients, 22 (27.5%) BMS patients and four
(5.9%) DES patients. All-cause and cardiovascular mortality rates were significantly lower in the
DES group compared to both the BMS and the brachytherapy groups (p = 0.01 and p = 0.001,
respectively).
Conclusions: DES application for in-stent restenosis and de novo lesions was superior to
brachytherapy and BMS application with respect to all-cause and cardiovascular mortalities.
(Cardiol J 2011; 18, 6: 654–661)
Key words: intracoronary brachytherapy, drug-eluting stent, bare-metal stent,
cardiovascular mortality
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Introduction
While stent application is effective in reducing
early-stage complications after balloon angioplas-
ty, it cannot completely overcome late-stage reste-
nosis. Therefore, researchers performing intraco-
ronary brachytherapy studies have recently focused
on the effects of ionized radiation on restenosis and
de novo lesions. Studies on intracoronary brachy-
therapy have demonstrated that it reduces neointi-
mal formation, especially during the initial months,
and leads to negative remodeling [1–5]. Failure to
completely prevent restenosis with stent proce-
dures or brachytherapy has resulted in the deve-
lopment of drug-eluting (paclitaxel, sirolimus coat-
ed) stent (DES) applications. Randomized studies
have shown that DES cause less restenosis than
bare-metal stents (BMS) [6–9].
Although the ability of brachytherapy and DES
to lessen restenosis has been demonstrated in some
studies, their contribution to clinical end-points is
an issue of greater importance. There is no data in
the literature comparing long-term (five years) clini-
cal outcomes of intracoronary brachytherapy, DES
and BMS applications.
Therefore, in the present study we aimed to
investigate the effects of brachytherapy, DES and
BMS applications in the treatment of coronary ar-




A total of 270 patients were treated with
brachytherapy, BMS or DES applications for coro-
nary artery lesions in our clinics between January
2000 and December 2003, of whom  217 were avail-
able for five year follow-up. Patients re-presenting
with angina and/or objective evidence of coronary
artery lesion in native vessel or by-pass graft as
demonstrated angiographically and who had under-
gone successful elective percutaneous revasculari-
zation were included in the study. In patients with
multiple artery disease, only one lesion was ope-
rated per artery. Patients re-presenting with arte-
ries of diameters between 2.5 and 4.0 mm, at high
risk for restenosis (diffuse, > 20 mm diseased seg-
ment, chronic total occlusion, saphenous graft or
presence of in-stent restenosis) and having de novo
or marked restenotic lesion (> 50%) were consi-
dered eligible. Patients with acute myocardial in-
farction (MI), new thrombotic lesions as evidenced
by angiography, and patients in whom aspirin or clo-
pidogrel was contraindicated and who received both
brachytherapy and stenting were excluded. Patients
were treated with only one of the following: beta-
-radiotherapy, BMS or DES. The drug in the DES
was paclitaxel. Written informed consent was ob-
tained from all patients before inclusion in the study
and the study was approved by the Ethics Commit-
tee of Erciyes University Medical Faculty.
Procedural details
All patients were given aspirin (100 mg, oral)
and clopidogrel (75 mg) at least a week before the
procedure, and 5,000 u heparin was administered
just before the procedure. Based on standard appli-
cations, percutaneous coronary intervention (PCI)
was performed using a femoral 8 Fr guiding cathe-
ter. In all procedures, brachytherapy, BMS or DES
were applied after an adequate opening was achie-
ved by balloon angioplasty.
BMS and DES stent application was carried out
in accordance with international guidelines which
set the basis for standard applications in our clinics.
Patients who received combined BMS and DES
were excluded from the study. Successful PCI was
defined as a lack of major complications after stent
implantation, < 30% decrease in target lesion and
TIMI flow grade being 3. The choice as to DES or
BMS was left to the operating physician. All DES
stents were paclitaxel-eluting.
Transfer-device enclosed strontium/yttrium
beta source was used for VBT and a 5 Fr catheter
(Novoste Beta-Cath) was used for intravascular
transfer. Complete administration (> 90%) of the
radiation dose, including interruptions, was consi-
dered successful brachytherapy. Recommended radia-
tion dose, determined based on arterial and stent
diameters, was administered from a distance of
2 mm. Following successful PCI, transfer catheter
was inserted to the arterial region through the wire.
The position of the radiation source was angiogra-
phically documented. The source device was 40 mm
long. A pull-back procedure was applied in case the
diseased segment could not be covered by the radia-
tion source. After completion of the radiation thera-
py, the transfer catheter was removed along with
the beta source and the procedure was completed
with angiographic imaging following administration
of intracoronary nitrate. Procedural success was de-
fined as the presence of 30% or less residual nar-
rowness at the final angiogram.
Measurable coronary angiography
Measurable coronary analysis was performed
offline using a CAAS 2 system. Measurements were
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performed before and after the operation. Minimal lu-
men diameter was estimated from the lesion borders
and the reference diameter was automatically calcu-
lated. The percentage stenosis diameter was calcula-
ted using minimal lumen and reference diameters.
Hospitalization and long term follow-up
Acute clinical success was accepted as a suc-
cessful procedure without a major cardiac event
during hospitalization. A major cardiac event was
defined as: death, MI or repeated revascularization
in any coronary arteries (PCI or CABG). MI was
diagnosed in the presence of two of the following
symptoms: chest pain lasting for at least 30 min;
newly developing pathological q waves; at least
doubling of the the normal CK-MB isoenzyme levels.
Myocardial infarcts, cardiovascular or all-cause
related morbidities, and revascularization proce-
dure for the target vessel (PTCA, CABG) data dur-
ing the five year follow-up were obtained from hos-
pital records, death certificates and direct contact
via telephone.
Statistical analysis
Chi-square tests and Fisher’s exact tests were
used for categorical variables. For continuous varia-
bles, the three groups were compared using ANOVA.
Correlation analyses were performed using the
Pearson coefficient of correlation. A probability
value of p < 0.05 was considered significant. Ka-
plan-Meier survival analysis was performed for sur-
vival analysis of all patients. All statistical analyses
were carried out using statistical software (SPSS,
version 15.0 for Windows; SPSS, Chicago, IL, USA).
Survival curves with a 95% confidence interval (CI)
were computed using the Kaplan-Meier method.
Cox regression was used to model five year mortali-
ty. The start-point was treatment with brachythera-
py or BMS or DES, and the end-point was either death
or the end of the fifth year of treatment. For multi-
variate analysis, only variables with a p value < 0.05
were entered into a Cox proportional hazards model
and selected using a stepwise selection procedure.
Hazard ratios (HR) and 95% CI were computed from
the estimated parameters of the final regression
model. Software package Stata 11 (StataCorp, Col-
lege Station, TX, USA) was used for the analysis.
Results
General clinical characteristics
General clinical characteristics are set out in
Table 1. There were no significant differences
among the three groups with respect to general
characteristics including age, gender, history of MI
and revascularization, clinical presentation, or car-
diovascular risk factors. Also, there were no signi-
ficant differences in mean baseline blood urea ni-
trogen or left ventricular ejection fraction (LVEF).
All patients were given clopidogrel (75 mg) at least
six months after the procedure, and the duration of
clopidogrel treatment did not vary between the
groups (p > 0.05; Table 1).
Angiographic properties
There were no significant differences among
the three groups with respect to parameters such
as vessel localization, in-stent restenosis/de novo
ratio and lesion characteristics (length, width, type
and narrowing percentage; Table 1).
Acute success and in-hospital events
Acute success was achieved in all patients. No
cases of death, new MI or revascularization were
seen in any of the three groups (Table 2).
Long-term follow-up results
Mean follow up duration was 5.1 ± 1.1 years
in the brachytherapy group, 4.7 ± 1.0 years in the
BMS group, and 4.9 ± 0.2 years in the DES group.
During the five year follow-up period, 25 pa-
tients (20 PTCA, five CABG)  in the brachytherapy
group, 22 patients (14 PTCA, eight CABG) in the
BMS group, and 11 patients (eight PTCA, three
CABG) in the DES group, had undergone revascu-
larization of the target vessel. Totals in terms of
revascularization, PTCA or CABG were not signifi-
cantly different between the groups (p = 0.29, 0.01
and 0.53, respectively; Table 2).
During the five year follow-up period, 22
(31.9%) patients in the brachytherapy group, 20
(25%) patients in the BMS group, and seven
(10.1%) patients in the DES group were hospitali-
zed due to MI. MI was significantly less frequent in
the DES group compared to both the BMS and the
brachytherapy groups (p = 0.03; Table 2).
During the five year follow-up period, the all-
cause mortality figure was 20 (29%) in the brachy-
therapy group, 22 (27.5%) in the BMS group, and
four (5.9%) in the DES group. Cardiovascular event
was the cause of death for 14 (20.3%) patients in
the brachytherapy group, 16 (20%) patients in the
BMS group and four (5.9%) patients in the DES
group. All-cause mortality and cardiovascular mor-
tality rates were significantly lower in the DES
group compared to both the BMS and the brachy-
therapy groups (p = 0.01 and p = 0.001, respec-
tively; Table 2).
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Table 2. Clinical five year follow-up of all patients.
Brachytherapy (n = 69) BMS  (n = 80) DES  (n = 68) P
Repeated revascularization 25 (36.2%) 22 (27.5%) 11 (16.8%) 0.29
PTCA 20 (29%) 14 (17.5%) 8 (11.8%) 0.01
CABG 5 (7.2%) 8 (10%) 3 (4.4%) 0.53
Myocardial infarction 22 (31.9%) 20 (25%) 7 (10.1%) 0.03
Death (all-causes) 20 (29%) 22 (27.5%) 4 (5.9%) 0.01
Cardiovascular death 14 (20.3%) 16 (20%) 4 (5.9%) 0.001
PTCA — percutaneous transluminal coronary angioplasty; CABG — coronary artery bypass grafting; BMS — bare-metal stent; DES — drug-eluting stent
Table 1. Demographic, clinical and angiographic characteristics of the patients (n = 217).
Brachytherapy (n = 69) BMS (n = 80) DES (n = 68) P
Age [years] 60.1 ± 9.5 55.7 ± 9.2 58.9 ± 9.8 0.44
Gender (male/female) 49/20 54/26 51/17 0.61
Prior MI 20 (29%) 20 (25%) 14 (20.6%) 0.25
Prior PCI 13 (18.8%) 10 (12.5%) 8 (11.8%) 0.23
Prior CABG 7 (10.1%) 6 (7.5%) 4 (5.9%) 0.35
Presentation:
STEMI 25 (36.2%) 22 (27.5%) 18 (26.5%) 0.21
Non-STEMI/UAP 27 (39.1%) 33 (41.3%) 27 (39.7%) 0.94
Stable angina 17 (24.6%) 25 (31.3%) 23 (33.8%) 0.24
LVEF, mean [%] 50.3 ± 10.3 48.6 ± 10.5 51.5 ± 9.7 0.22
NYHA
1 46 (66.7%) 57 (71.3%) 51 (75%) 0.28
2 17 (24.6%) 18 (25%) 12 (17.6%) 0.32
3 6 (8.7%) 5 (6.3%) 4 (5.9%) 0.51
BUN [mg/dL] 19.3 ± 8.5 17.3 ± 7.3 18.2 ± 8.3 0.35
Clopidogrel use [months] 15.1 ± 3.4 15.5 ± 3.6 16.3 ± 3.7 0.13
Cardiovascular risk factors:
Diabetes mellitus 21 (30.4%) 28 (35%) 30 (44.1%) 0.09
Hypertension 24 (34.8%) 32 (40%) 32 (47.1%) 0.14
Hyperlipidemia 34 (49.3%) 32 (40%) 34 (50%) 0.93
Smoker 37 (53.6%) 54 (67.5%) 44 (64.7%) 0.18
In-stent restenosis/de novo 28/41 32/48 30/38 0.67
Location of lesions:
    LAD 26 (37.7%) 32 (40%) 30 (44.1%) 0.67
RCA 22 (31.9%) 28 (35%) 18 (26.5%) 0.43
CX 16 (23.2%) 16 (20%) 16 (23.5%) 0.96
Saphenous graft 5 (7.2%) 4 (5%) 4 (5.9%) 0.78
Width of lesions 2.97 ± 0.40 3.15 ± 0.35 3.0 ± 0.37 0.17
Length of lesions 13.8 ± 7.6 16.0 ± 5.0 15.5 ± 6.0 0.36
Type of lesions:
A 10 (14.5%) 18 (22.5%) 19 (27.9%) 0.65
B1 28 (40.6%) 26 (32.5%) 14 (20.6%) 0.23
B2 16 (23.2%) 20 (25%) 21 (30.9%) 0.47
C 15 (21.7%) 16 (20%) 14 (20.6%) 0.83
Percentage of narrowing (QCA):
50–70% 10 (14.5%) 2 (2.5%) 0 0.11
70–90% 31 (44.9%) 38 (47.5%) 34 (50%) 0.78
90–99% 11 (15.9%) 22 (27.5%) 21 (30.9%) 0.28
99% (subtotal) 7 (10.1%) 8 (10%) 9 (13.2%) 0.77
100% (total) 10 (14.5%) 10 (12.5%) 4 (5.9%) 0.53
MI — myocardial infarction; PCI — percutaneous coronary intervention; CABG — coronary artery bypass grafting; STEMI — ST elevation myocardial
infarction; UAP — unstable angina pectoris; LVEF — left ventricular ejection fraction; NYHA — New York Heart Association; BUN — blood urea nitro-
gen; LAD — left anterior descending coronary artery; RCA — right coronary artery; CX — circumflex coronary artery
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Demographic, clinical, and angiographic chara-
cteristics of the death and survival groups are de-
tailed in Table 3. Regarding the basic clinical and
demographic characteristics, the death and survi-
val groups were similar in terms of gender, history
of PCI and CABG, lesion localization, in-stent res-
tenosis/de novo ratio and lesion characteristics
(length, width, type and narrowing percentage;
p > 0.05). Additionally, smoking, hypertension and
hypercholesterolemia were similar in the two
groups (p > 0.05; Table 3). However, the preva-
lence of diabetes mellitus and prior MI were signif-
icantly higher in the death group than in the sur-
vival group (p = 0.02; Table 3). Similarly, mean age
was higher in the death group (p = 0.02; Table 3).
Also, admission with ST elevation MI (STEMI) and
NYHA class III were the most frequent clinical pre-
sentations in the death group (p = 0.003; Table 3).
Table 3. Demographic, clinical and angiographic characteristics of the death and survival groups (n = 217).
Death group  (n = 46) Survival group  (n = 171) P
Age [years] 61.4 ± 11.4 57.2 ± 8.9 0.02
Gender (male/female) 28/18 126/45 0.09
Prior MI 17 (37%) 37 (21.6%) 0.03
Prior PCI 7 (15.2%) 24 (14%) 0.83
Prior CABG 5 (10.9%) 12 (7%) 0.38
Presentation:
STEMI 22 (42.8%) 43 (25.1%) 0.003
Non-STEMI/UAP 14 (30.4%) 73 (42.7%) 0.13
Stable angina 10 (21.7%) 55 (32.2%) 0.17
LVEF, mean [%] 46.6 ± 11.1 51.0 ± 9.8 0.01
NYHA:
1 27 (58.7%) 127 (74.3%) 0.04
2 12 (26.1%) 35 (20.5%) 0.41
3 7 (15.1%) 8 (4.7%) 0.01
BUN [mg/dL] 17.9 ± 6.8 18.3 ± 8.3 0.77
Treatments:
Brachytherapy group (n = 69) 22 (47.8%) 47 (27.5%) 0.009
BMS group (n = 80) 20 (43.5%) 60 (35.1%) 0.29
DES group (n = 68) 4 (8.7%) 64 (37.4%) < 0.001
Cardiovascular risk factors:
Diabetes mellitus 23 (50%) 56 (32.7%) 0.02
Hypertension 16 (34.8%) 72 (42.1%) 0.23
Hyperlipidemia 26 (56.5%) 74 (43.3%) 0.07
Smoker 29 (63%) 106 (62%) 0.51
In-stent restenosis/de novo 24/22 66/105 0.07
Location of lesions:
LAD 14 (30.4%) 74 (43.3%) 0.22
RCA 12 (26.1%) 56 (32.7%) 0.45
CX 17 (37%) 31 (18.1%) 0.12
Saphenous graft 3 (6.5%) 10 (5.8%) 0.64
Width of lesions 3.03 ± 0.41 3.05 ± 0.35 0.78
Length of lesions 14.5 ± 6.8 15.8 ± 5.7 0.25
Type of lesions:
A 12 (26.1%) 35 (20.5%) 0.44
B1 17 (37%) 51 (29.8%) 0.25
B2 10 (21.7%) 47 (27.5%) 0.71
C 7 (15.2%) 38 (22.2%) 0.37
Percentage of narrowing (QCA):
50–70% 1 (2.2%) 11 (6.4%) 0.21
70–90% 27 (58.7%) 76 (44.4%) 0.33
90–99% 9 (19.6%) 45 (26.3%) 0.51
99% (subtotal) 4 (8.7%) 20 (11.7%) 0.62
100% (total) 5 (10.9%) 19 (11.1%) 0.81
Abbreviation as in Table 1
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Significantly fewer patients were treated with DES
in the death group, and additionally, mean LVEF
was significantly lower in the death group compared
to the survival group (46.6 ± 11.1 vs 51.0 ± 9.8;
p = 0.01; Table 3).
Patients treated with DES had the highest
probability of survival (Fig. 1). Estimated standard
error, p value, and HR as a function of the risks of
the variables according to the Cox proportional
hazards model are set out in Table 4. Significant re-
lations with total mortality were observed for in-
creasing age, DES use and admission with STEMI
(Table 4).
Discussion
Percutaneous angioplasty is one of the com-
monest treatment procedures for CAD. Stent tech-
nology has developed over recent decades, in or-
Table 4. Estimated standard error (SE), p value, and hazard ratio (HR) as a function of the risks of the
variables according to the Cox proportional hazards model.
Risk factors SE P HR 95% CI
Brachytherapy 0.34 0.92 1.03 0.54–1.97
BMS 0.33 0.90 0.96 0.50–1.85
DES 0.09 0.001 0.18 0.06–0.49
Age 0.02 0.007 1.05 1.01–1.08
STEMI 0.02 0.003 2.43 1.36–4.34
NYHA class 1 0.27 0.47 0.77 0.39–1.54
NYHA class 3 0.49 0.95 0.96 0.35–2.66
LVEF 0.01 0.08 0.97 0.94–1.00
CI — confidence interval; BMS — bare-metal stent; DES — drug-eluting stent; STEMI — ST elevation myocardial infarction; NYHA — New York Heart
Association; LVEF — left ventricular ejection fraction
der to prevent both coronary dissections and long-
-term restenosis development following balloon an-
gioplasty. Initially, the use of non-drug-eluting
stents resulted in problems including restenosis,
which led to the development of drug-coated stents
and the use of brachytherapy with beta radiation.
Although brachytherapy is now considered an out-
dated approach, the literature does not include
many long-term studies which have clinically com-
pared this approach to stent technology.
Ours is the first study comparing brachythera-
py, BMS and DES with regards to survival. Our
results have demonstrated the superiority of DES
in groups of patients with de novo and in-stent res-
tenosis lesions.
Previous studies have compared brachythera-
py to DES in in-stent restenosis cases. In their
study of 50 patients, Feres et al. [10] showed the
superiority of DES to brachytherapy in in-stent res-
tenosis. During the initial 12-month follow-up pe-
riod, revascularization was required in almost one-
-third of the patients who received beta radiation for
in-stent lesions. Pohl et al. [11] also demonstrated
the superiority of drug coated stents to brachythera-
py in terms of repetitive revascularization rates
and the prevention of angiographic lumen loss in
patients with in-stent restenosis. In contrast to
these studies, the present study is the first to com-
pare DES use to brachytherapy in a patient group
including not only in-stent restenosis cases, but also
cases with de novo lesions. Despite these two groups
being similar with respect to in-hospital events,
there were significant differences at the clinical
end-points of the long-term follow-up.
At the end of the five year follow-up period, all-
cause and cardiovascular event related mortality
rate, mainly including non-fatal MIs, was significant-
ly lower in the DES group. There was no signifi-
Figure 1. Kaplan-Meier survival estimates by treatment.
The patients with DES treatment have the highest pro-
bability of survival.
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cant difference between the groups with respect to
revascularization rate. The observation of fewer
deaths, but a similar revascularization rate in the
DES group compared to the other groups, suggests
that MI events recorded in this group were mostly
non-fatal.
In their study of 235 patients (150 BMS and
85 DES), Yang et al. [12] did not record any in-hos-
pital event. Similarly to the study of Condado et al.
[13] of 21 patients, no cardiac event was noted fol-
lowing brachytherapy in the present study.
Repeating MIs in patients who had undergone
angioplasty is the most important cause of mortali-
ty and morbidity. In their study of 61 patients who
received brachytherapy, Nikas et al. [14] reported
an 8% MI rate during 43 months of follow-up. Pfis-
terer et al. [15] reported a 13% MI rate during three
years of follow-up of 545 patients who had received
DES. In the present study, the MI rate during the
five-year follow-up was 32% in the brachytherapy
group and 10% in the DES group.
We believe that the most important reason for
the higher MI rate reported in the brachytherapy
group is the high DM rate recorded in this group
and the longer follow-up duration. Given that DES
may introduce significant benefits, especially to dia-
betic patients, its superiority to brachytherapy is an
expected outcome.
In their studies on brachytherapy, Feres et al.
[10] reported that beta radiation causes acellulari-
ty in the vessel segments where it is applied, re-
sulting in aggregation of macrophages and throm-
bocytes on these regions, especially after the first
six months, which leads to an increased tendency
for late-stage thrombosis. It has also been demon-
strated that adequate radiation of the whole area of
vessel damage seen after balloon procedure results
in plaque formation originating especially from the
lesion borders. These factors may have led to the
high MI rates recorded in the brachytherapy group
in the present study.
The SISR study [16] has demonstrated the clini-
cal and angiographic benefits of drug-coated stents
compared to vascular brachytherapy. The superi-
ority of drug coated stents seen during long term
clinical follow-ups may also be associated with the
presence of in-stent stenosis in these patient groups.
The operated lesions of some patients in this study
were in-stent restenosis. Currently, DES is pre-
ferentially indicated in this patient group.
Meta-analyses of randomized trials and large
registry studies demonstrate that the use of DES
generally leads to better clinical outcomes for pa-
tients with or without diabetes mellitus [17–19].
Additionally, another study observed a low rate of
late stent thrombosis and superior efficacy results
in DES patients [20]. Less late stent thrombosis
may be the plausible explanation of the low death
rates observed in the DES treatment group.
LVEF is well-known to predict outcomes in
patients with CAD [21]. The magnitude of functional
status (NYHA) before stenting differed between the
groups.This study showed that mean LVEF was
significantly lower in the death group compared to
the survival group.
The present study is the first to clinically com-
pare brachytherapy to BMS. The use of BMS did
not lead to a significant difference in the rates of
MI, revascularization, cardiovascular or all-cause
mortalities during in-hospital and long-term
follow-up compared to brachytherapy.
Limitations of this study
Limitations were the small number of patients,
the retrospective nature, the incomplete follow-up,
the single-center design, the mixed cohort of both
in-stent restenosis and de novo lesions, and the po-
tential bias in the non-randomized selection of treat-
ment strategy. Additionally, the BNP/NT-proBNP
levels were not measured.
Conclusions
Among the treatment options available for
CAD, DES application provides lower all-cause
mortality and cardiovascular mortality rates com-
pared to BMS or brachytherapy. These findings
support the cessation of brachytherapy application,
as one which although previously used with enthu-
siasm, has not achieved the desired outcomes.
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